Acta Pharmacologica Sinica, 40(10), 12901298
Based on these data A-GSH targeting may increase the initial binding step of nanocarrier cell entry that in turn would lead to increased endocytosis
Along with the new oral version of the GLP-1 agonist that has made a strong commercial start since its launch in the US earlier this year, the high-dose injectable version is one of the assets Novo Nordisk is hoping will help staunch the loss in market share in obesity caused by the rapid growth of Wegovy's main rival, Eli Lilly's Zepbound/Mounjaro (tirzepatide), which outperformed the original 2.4 mg Wegovy formulation in head-to-head trials
Date la sua potenziale capacit brucia-grassi, si pensa che la L-Carnitina ottimizzi il modo in cui il corpo usa il grasso come carburante, permettendo allenamenti pi lunghi
Zelante T, Iannitti RG, Cunha C, et al